FDA Inspection 1031416 — Niagara Pharmaceuticals Inc
The FDA completed an inspection of Niagara Pharmaceuticals Inc on Sep 18, 2017 in Dundas. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Sep 18, 2017
- Fiscal Year
- 2017
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Dundas (Canada)